RareCyte launches prostate cancer ARv7 CTC Kit for liquid biopsy analysis
- Wednesday, October 30, 2019, 7:06
- Finance
- Add a comment
SEATTLE, Oct. 30, 2019 /PRNewswire/ — RareCyte announces the launch of a new RarePlex® Staining Kit, enabling customers to evaluate prostate cancer specific expression of ARv7 on circulating tumor cells (CTC) in their own laboratory. ARv7 is the result of a splice variant of Androgen…
About the Author
adminasapcorp has written 41279 stories on this site.